yahoo_financeOriginal article
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
ConferenceNeflamapimodPositive
AI Analysis
Summary
CervoMed announced new clinical, plasma biomarker, and imaging data for neflamapimod in dementia with Lewy bodies at the AAIC 2026 conference.
Importance:5/10
Sentiment:
0.30
clinical databiomarker dataimaging dataAAIC 2026neflamapimoddementiaDLB
Related Companies
Read the original article
Published by yahoo_finance on July 14, 2026 11:30 AM